02:50 PM EST, 11/20/2024 (MT Newswires) -- PainReform ( PRFX ) attributed "incoherence of data" to unclear results in the latter portion of a phase 3 trial evaluating its PRF-110 drug candidate as a non-opioid alternative treatment for post-surgical pain.

Shares slumped 28%, with intraday trading volume at over 4.49 million compared with a daily average of about 415,000.

Target ( TGT ) slashed its full-year earnings outlook amid soft consumer discretionary spending trends, while fiscal Q3 results missed market estimates.

Shares sank 21% as intraday trading volume jumped to over 52.6 million, versus a daily average of about 4.1 million.

Price: 1.01, Change: -0.39, Percent Change: -27.86